top of page

We invite you to engage in an interactive roundtable led by EverythingALS consortia members of neurologists, industry partners, scientists, novel sensor and AI companies, regulators and patients to help advance the discovery and implementation of ALS digital biomarkers in clinical trials through our collaborative efforts.

 

Joining our participatory roundtable, you will be the first to learn about our latest study results on ALS digital biomarkers as well as have the opportunity to hear why major pharmaceutical companies have joined the consortium to partner in our research, which will be expanded to include analyzing data from wearables and smartphones.

  

As always, we approach each roundtable to encourage out-of-the-box thinking, and to kick it off, we have an exciting agenda! Take a look below. 

This is an invite only event.

Speakers

Hosts & Speakers 

  • Twitter
  • LinkedIn
  • LinkedIn
  • LinkedIn
  • LinkedIn
  • icons8-link-60
  • icons8-link-60
    • Twitter
    • LinkedIn
    • icons8-link-60
    • LinkedIn
    • LinkedIn
    • LinkedIn
    • LinkedIn
    Agenda
    Untitled (1226 x 322 mm) (3)_edited.jpg

    Agenda

    December 09, 2022  - 12PM ET I 9AM PT


    1 pm - 1:30 pm ET is a Closed session for Consortia Members only

    10 minutes

    10 minutes

    10 minutes

    15 minutes

    15 minutes

    Welcome/Consortia Updates/Partnerships

    Indu Navar - CEO and Founder, EverythingALS

    James Berry, MD - Neurologist at MGH 

    Keynote: Living with ALS perspective

    John Driskell Hopkins GRAMMY Award winner, Zac Brown Band  

    Speech Study Updates

    Ernest Frankel, PhD - MIT

    Accelerating pre-competitive Partnerships, ALS Therapies & Digital Biomarkers

    Walter Koroshetz, MD NIH, Deputy Director National Institute of Neurological Disorders and Stroke (NINDS)

    Role of Digital Biomarkers & Clinical Endpoints

    Brendan O'Leary - FDA, Acting Director, Digital Health Center of Excellence

    5 minutes

    25 minutes

     

    Open dialogue with NIH & FDA

    Moderated by Wendy Ehler

    Closing remarks and next steps  

    Indu Navar

    Participants

    bottom of page